

# Jakob Schllhammer Knudsen

## List of Publications by Citations

### Source:

<https://exaly.com/author-pdf/4202060/jakob-schollhammer-knudsen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24

papers

109

citations

7

h-index

10

g-index

24

ext. papers

186

ext. citations

6.8

avg, IF

2.92

L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 24 | Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats. <i>British Journal of Pharmacology</i> , 2017, 174, 2563-2575  | 8.6  | 21        |
| 23 | Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. <i>PLoS ONE</i> , 2020, 15, e0229621   | 3.7  | 16        |
| 22 | Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. <i>Sexual Medicine Reviews</i> , 2019, 7, 430-441   | 5.6  | 13        |
| 21 | Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Diabetes Care</i> , 2018, 41, e133-e135  | 14.6 | 12        |
| 20 | Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries. <i>British Journal of Pharmacology</i> , 2019, 176, 386-399   | 8.6  | 9         |
| 19 | Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels. <i>JAMA Network Open</i> , 2020, 3, e1920949   | 10.4 | 8         |
| 18 | Acute pancreatitis: 31-Year trends in incidence and mortality - A Danish population-based cohort study. <i>Pancreatology</i> , 2020, 20, 1332-1339  | 3.8  | 7         |
| 17 | Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 520-529  | 6.7  | 7         |
| 16 | Trends in HbA and LDL Cholesterol in Patients With Type 2 Diabetes Receiving First-Time Treatment in Northern Denmark, 2000-2017: Population-Based Sequential Cross-Sectional Analysis. <i>Diabetes Care</i> , 2020, 43, e17-e19  | 14.6 | 6         |
| 15 | Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. <i>Journal of the American Heart Association</i> , 2021, 10, e019356   | 6    | 4         |
| 14 | Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study. <i>Journal of Diabetes</i> , 2019, 11, 690-694   | 3.8  | 3         |
| 13 | Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study.. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100291   | 1    |           |
| 12 | Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. <i>Diabetes Care</i> , 2021,  | 14.6 | 1         |
| 11 | Development and validation of a model for predicting mortality in patients with hip fracture.. <i>Age and Ageing</i> , 2021,  | 3    | 1         |
| 10 | A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2354-2363   | 6.7  | 0         |
| 9  | Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - A Danish population-based study. <i>Lupus</i> , 2021, 30, 228-237  | 2.6  | 0         |
| 8  | Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital.. <i>Clinical Epidemiology</i> , 2022, 14, 159-171 | 5.9  |           |

## LIST OF PUBLICATIONS

- 7 Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997-2017: Time trends in incidence and HbA and glucose-lowering drug use before and after hypoglycaemia. *Endocrinology, Diabetes and Metabolism*, **2021**, 4, e00227 2.7
- 6 Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study **2020**, 15, e0229621
- 5 Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study **2020**, 15, e0229621
- 4 Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study **2020**, 15, e0229621
- 3 Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study **2020**, 15, e0229621
- 2 Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study **2020**, 15, e0229621
- 1 Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study **2020**, 15, e0229621